Sustained Release Oral Formulation for Treatment of Parkinson's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
Achieving sustained blood levels of carbidopa/levodopa has been a challenge in the treatment of PD and although levodopa remains the most commonly used drug, motor fluctuations remain a major disability especially in advanced Parkinson\'s disease. The aim of this study is to determine the efficacy of a novel oral carbidopa-levodopa formulation in achieving a sustained blood level of levodopa and carbidopa in PD.
Epistemonikos ID: a0b9cabbd82e8b15f1adf1f96d16b5c5ad03fcf9
First added on: May 13, 2024